DE68919010D1 - Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Präparate. - Google Patents

Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.

Info

Publication number
DE68919010D1
DE68919010D1 DE68919010T DE68919010T DE68919010D1 DE 68919010 D1 DE68919010 D1 DE 68919010D1 DE 68919010 T DE68919010 T DE 68919010T DE 68919010 T DE68919010 T DE 68919010T DE 68919010 D1 DE68919010 D1 DE 68919010D1
Authority
DE
Germany
Prior art keywords
4alkyl
hydrogen
processes
preparation
pharmaceutical preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68919010T
Other languages
English (en)
Other versions
DE68919010T2 (de
Inventor
William John Coates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Application granted granted Critical
Publication of DE68919010D1 publication Critical patent/DE68919010D1/de
Publication of DE68919010T2 publication Critical patent/DE68919010T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE68919010T 1988-07-25 1989-07-19 Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Präparate. Expired - Fee Related DE68919010T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888817651A GB8817651D0 (en) 1988-07-25 1988-07-25 Chemical compounds

Publications (2)

Publication Number Publication Date
DE68919010D1 true DE68919010D1 (de) 1994-12-01
DE68919010T2 DE68919010T2 (de) 1995-04-06

Family

ID=10641046

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68919010T Expired - Fee Related DE68919010T2 (de) 1988-07-25 1989-07-19 Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.

Country Status (10)

Country Link
US (1) US5073559A (de)
EP (1) EP0352960B1 (de)
JP (1) JPH0288577A (de)
AT (1) ATE113284T1 (de)
AU (1) AU613503B2 (de)
DE (1) DE68919010T2 (de)
DK (1) DK363689A (de)
GB (1) GB8817651D0 (de)
PT (1) PT91231B (de)
ZA (1) ZA895613B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
FI951367A (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO1998019672A1 (en) * 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
DE19702785A1 (de) * 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
KR100441229B1 (ko) * 1997-04-25 2004-07-22 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트 포스포디에스테라제(ｃＧＭＰ ＰＤＥ5)를 억제하는 성기능 장애 치료용 피라졸로피리미디논
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
CN100430396C (zh) 1997-11-12 2008-11-05 拜耳医药保健股份公司 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
DK1371647T3 (da) 1998-04-20 2005-10-17 Pfizer Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
KR20020038941A (ko) 1999-10-11 2002-05-24 디. 제이. 우드, 스피겔 알렌 제이 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
CN100439370C (zh) * 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
DE50209015D1 (de) * 2001-05-09 2007-02-01 Bayer Healthcare Ag NEUE VERWENDUNG VON 2-Ä2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenylÜ-5-methyl-7-propyl-3H-imidazoÄ5,1-fÜÄ1,2,4Ütriazin-4-on
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
EP1312363A1 (de) * 2001-09-28 2003-05-21 Pfizer Products Inc. Behandlungsverfahren und kits bestehend aus Wachstumshormonsekretionsförderern
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
AU2003261418B2 (en) * 2002-08-08 2010-05-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
AU2003264017B2 (en) * 2002-08-08 2010-05-27 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
WO2004032861A2 (en) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
ES2341545T3 (es) * 2003-06-06 2010-06-22 Arexis Ab Uso de compuestos heterociclicos condensados como inhibidores de scce para el tratamiento de enfermedades de la piel.
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1931797A2 (de) * 2005-09-29 2008-06-18 Bayer HealthCare AG Pde-inhibitoren und kombinationen davon zur behandlung urologischer störungen
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
US20110190192A1 (en) * 2009-12-15 2011-08-04 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
CN104710323B (zh) * 2013-12-11 2018-05-15 中国疾病预防控制中心寄生虫病预防控制所 具有杀螺活性的水杨酰胺酯类化合物及其制备和用途
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators

Also Published As

Publication number Publication date
EP0352960A2 (de) 1990-01-31
DK363689D0 (da) 1989-07-21
DK363689A (da) 1990-01-26
PT91231B (pt) 1995-03-01
EP0352960A3 (de) 1991-11-06
JPH0288577A (ja) 1990-03-28
DE68919010T2 (de) 1995-04-06
EP0352960B1 (de) 1994-10-26
US5073559A (en) 1991-12-17
AU3821089A (en) 1990-01-25
PT91231A (pt) 1990-02-08
ZA895613B (en) 1990-05-30
AU613503B2 (en) 1991-08-01
GB8817651D0 (en) 1988-09-01
ATE113284T1 (de) 1994-11-15

Similar Documents

Publication Publication Date Title
DE68919010D1 (de) Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.
DK602589D0 (da) Quinazolinonderivater
DK0539204T3 (da) Antivirale 4-substituerede-deoxy-2,3-didehydroderivater af alfa-D-neuraminsyre
DE69300532D1 (de) Naphtylalkylamine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
MX9203550A (es) Derivados de 4-aminoquinolina y su uso como medicamentos.
FR2694004B1 (fr) Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
DE68901153D1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
DE68917220D1 (de) Phenylpyridon-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
ES2053946T3 (es) Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-onas.
AU530678B2 (en) Phosphono-hydroxy-acetic acid
DE69300296D1 (de) Thiochromanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
ZA935277B (en) Aminoalkylchromones processes for the preparation thereof and pharmaceutical compositions containing them
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE41770T1 (de) Derivate von n-(2-pyrrolidinylmethyl)benzamid, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zubereitung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee